04/02/2020 - Update on InnomarPharmacy and InnomarClinic hours and availability
InnomarClinics remain open to our patients amidst coronavirus (COVID-19) concerns.
Welcome to Canada. Let us support you through your journey.
For manufacturers new to the Canadian healthcare system, understanding our diverse regulatory and reimbursement landscape can be daunting. With 10 provinces and three territories—each with its own approach to public drug coverage, review processes, timelines and priorities—you need an experienced partner with in-depth knowledge to help guide your successful commercialization strategy.
When do I start planning my commercialization strategy?
A successful product launch starts with early and thorough planning. Timelines for regulatory and importation approval, health technology assessment, and market access submissions can take up to two years. We can help create efficiencies in that process by coordinating the timing of Health Canada drug submissions and drug establishment license applications through our TPIReg™ services, and initiating your product reimbursement strategy well in advance of market authorization. Our team at InnomarConsulting™ specializes in the strategic timing of submissions to help ensure a successful launch.
The right partner for a manufacturer who is new to Canada, is someone who is easy to work with, understands the landscape and understands our patients and physicians. Ultimately, you want a turnkey partner who is not just a consultant, but can also do the work.
It all comes down to data
Specialty pharmaceuticals and personalized medications demonstrate incredible promise to solve previously unmet clinical challenges. However, in response to the higher cost of these drugs, private payers have implemented significant changes to how they review claims. Payers have a responsibility to deliver long-term sustainability for their plans, and therefore must justify the investment in these new medications. Canadian payers are looking to pharmaceutical companies to present real-world data that demonstrate both the clinical- and cost-effectiveness of their products. Our Heath Economics and Outcomes Research (HEOR) team can assist with building data collection strategies which are meaningful and relevant to payers and customized to manufacturer needs.
Learn more about our HEOR services
We’re here for you at every step
Innomar Strategies doesn’t just consult on how to enter the Canadian market, we help you operationalize and deliver a consistent patient experience at every touch-point. Learn more about how our integrated services optimize product performance and enhance patient care.
Seamless service solutions to guide your way
We’ve developed a full suite of services to deliver end-to-end support for every stage of the product lifecycle. Here are just a few ways we make it easier to enter the Canadian market:
